Menu Search
Equities

Abbisko Cayman Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
8ZD:STU

Abbisko Cayman Ltd

Actions
  • Price (EUR)1.39
  • Today's Change0.03 / 2.21%
  • Shares traded0.00
  • 1 Year change+135.59%
  • Beta1.2787
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Abbisko Cayman Ltd is a research and development-driven, clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company's clinical-stage drug candidates include ABSK011 inhibitors, ABSK091 inhibitors, ABSK021 inhibitors and ABSK081 antagonists. The Company's selective preclinical stage drug candidates include ABSK043 inhibitors, ABSK061 inhibitors, ABSK121 inhibitors, ABSK012 inhibitors, ABSK111 inhibitors, ABSK071 inhibitors, ABSK051 inhibitors, and ABSK031 antagonists.

  • Revenue in HKD (TTM)698.64m
  • Net income in HKD169.32m
  • Incorporated2018
  • Employees226.00
  • Location
    Abbisko Cayman LtdBuilding 3, No. 898Halei Road, Zhangjiang Hi-Tech ParkPudong New AreaSHANGHAI 200120ChinaCHN
  • Phone+86 2 168912098
  • Websitehttps://www.abbisko.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.